A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
Watson plans to immediately begin shipping its generic versions of Sanofi’s hypertension treatment Avapro after receiving FDA approval to market the generic version. Watson will have a slew of generic competitors for irbesartan, including Lupin, which received ANDA approval Oct. 15, Mylan, Sandoz, Teva and Dr. Reddy’s. Watson will offer the 75-mg, 150-mg and 300-mg versions of the drug. Generic Line